Key facts
- This page summarizes MIRA PHARMACEUTICALS, INC.'s Form 3 filing for Telomir Pharmaceuticals, Inc. (TELO).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Oct 2025, 20:00.
MIRA PHARMACEUTICALS, INC. - 29 Sep 2025 Form 3 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TELO
- Reported as of
- 29 Sep 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/ Erez Aminov, CEO
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
MIRA PHARMACEUTICALS, INC. filed Form 3 for Telomir Pharmaceuticals, Inc. (TELO) on 03 Oct 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001904286
Primary reporting owner
MIRA PHARMACEUTICALS, INC.
- Relationship
- 10%+ Owner
- Address
- 1200 BRICKELL AVE. SUITE 1950 #1183, MIAMI
- Signature
- /s/ Erez Aminov, CEO
- Signature date
- 03 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TELO
holding
Common Stock, no par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,521,127
- Date
- 29 Sep 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents 3,521,127 shares of the Issuer's common stock, no par value, acquired in connection with the Reporting Person's acquisition of SKNY Pharmaceuticals, Inc.